Last 48 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 7.87 | 9.61 | 12.24 | 18.73 | 15.15 | 36.20 | 56.29 | 21.55 | 20.09 | 259.83 | — | 4263.75 | 339.67 | — | — | 31.23 | 20.74 | 282.08 | 51.64 | 18.79 | 182.25 |
| — | -73.5% | -78.3% | -13.1% | -24.6% | -86.1% | — | -99.5% | -94.1% | — | — | +13551.5% | +1537.9% | — | — | +66.2% | -88.6% | +1592.3% | +188.5% | -68.4% | +1551.6% | |
| P/S Ratio | 2.58 | 3.69 | 4.37 | 5.26 | 4.34 | 4.91 | 3.23 | 3.81 | 3.87 | 3.39 | 3.02 | 3.30 | 2.42 | 2.45 | 3.02 | 3.68 | 3.31 | 2.63 | 2.61 | 3.25 | 2.50 |
| — | -24.9% | +35.5% | +38.1% | +12.0% | +44.7% | +7.0% | +15.3% | +59.7% | +38.6% | -0.2% | -10.2% | -26.7% | -6.9% | +15.7% | +13.1% | +32.4% | +7.6% | -12.4% | +20.1% | +6.1% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | 2.04 | 1.73 | 1.65 | 1.78 | 2.48 | 2.50 | 2.18 | 2.11 | 2.40 | 1.95 |
| — | — | — | — | — | — | — | — | — | — | — | -17.7% | -30.8% | -24.4% | -15.6% | +3.5% | +28.2% | +22.2% | -1.6% | +27.4% | +7.4% | |
| P/FCF | 114.29 | 15.82 | 6.76 | — | — | — | 6.96 | 14.47 | — | — | 10.74 | 12.43 | 8.85 | 10.54 | — | 11.58 | 19.48 | 34.01 | 6.19 | 143.77 | 8.16 |
| — | — | -2.9% | — | — | — | -35.2% | +16.4% | — | — | — | +7.4% | -54.5% | -69.0% | — | -91.9% | +138.7% | — | -32.0% | +1306.1% | -23.5% | |
| EV / EBITDA | 6.03 | 7.48 | 9.64 | 12.41 | 12.54 | 14.61 | 12.19 | 14.26 | 11.60 | 86.67 | — | 26.66 | 18.86 | 12.11 | 131.92 | 26.47 | 11.63 | 27.10 | 15.55 | 24.81 | 24.11 |
| — | -48.8% | -20.9% | -12.9% | +8.1% | -83.1% | — | -46.5% | -38.5% | +615.7% | — | +0.7% | +62.2% | -55.3% | +748.1% | +6.7% | -51.8% | +157.8% | +35.3% | +24.4% | +216.6% | |
| EV / EBIT | 13.96 | 7.40 | 9.70 | 14.35 | 18.30 | 31.00 | 12.19 | 14.26 | 11.60 | 115.56 | — | — | 393.90 | 36.73 | — | 64.85 | 17.47 | 428.84 | 38.97 | 34.73 | 56.78 |
| — | -76.1% | -20.4% | +0.6% | +57.7% | -73.2% | — | — | -97.1% | +214.6% | — | — | +2155.3% | -91.4% | — | +86.7% | -69.2% | +3522.8% | +205.3% | +49.7% | +603.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.1% | 85.7% | 85.7% | 87.4% | 82.1% | 80.3% | 82.8% | 83.5% | 92.3% | 77.5% | 73.6% | 88.6% | 88.1% | 87.3% | 84.4% | 84.7% | 86.3% | 85.4% | 88.0% | 88.2% | 89.3% |
| — | +6.8% | +3.5% | +4.7% | -11.0% | +3.5% | +12.5% | -5.9% | +4.8% | -11.2% | -12.9% | +4.6% | +2.1% | +2.2% | -4.0% | -4.0% | -3.4% | -2.7% | +6.9% | -0.4% | +2.6% | |
| Operating Margin | 21.4% | 50.8% | 46.6% | 43.2% | 34.1% | 31.5% | 23.8% | 24.8% | 32.1% | 1.3% | -39.5% | -2.2% | -0.6% | 5.3% | -13.0% | 3.4% | 20.5% | -0.9% | 6.7% | 1.3% | 3.8% |
| — | +61.3% | +95.7% | +74.2% | +6.1% | +2319.9% | +160.4% | +1230.4% | +5396.4% | -75.4% | -204.2% | -165.2% | -103.0% | +715.9% | -294.4% | +161.0% | +435.2% | -103.9% | -72.4% | -87.2% | -87.2% | |
| Net Margin | 16.9% | 38.5% | 35.6% | 28.1% | 28.5% | 13.4% | 6.0% | 17.7% | 19.7% | 1.3% | -32.4% | 0.1% | 0.7% | -10.4% | -0.6% | 11.0% | 15.2% | 1.0% | 4.6% | 16.8% | 1.5% |
| — | +187.7% | +496.8% | +58.9% | +44.4% | +926.6% | +118.4% | +20374.2% | +2659.4% | +112.5% | -5192.3% | -99.2% | -95.3% | -1152.7% | -113.3% | -34.4% | +891.8% | -93.2% | -72.4% | +286.2% | -92.8% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | -24.0% | 0.0% | 0.1% | -1.7% | -0.1% | 1.9% | 2.9% | 0.2% | 0.9% | 3.1% | 0.3% |
| — | — | — | — | — | — | — | — | — | — | -26366.9% | -99.3% | -95.6% | -944.6% | -109.6% | -39.5% | +875.9% | -92.4% | -69.4% | +310.2% | -92.9% | |
| ROA | 16.6% | 10.7% | 10.0% | 7.4% | 7.8% | 2.9% | 1.3% | 3.5% | 4.2% | 0.3% | -6.8% | 0.0% | 0.1% | -1.2% | -0.1% | 1.0% | 1.5% | 0.1% | 0.5% | 1.5% | 0.2% |
| — | +264.7% | +688.5% | +112.5% | +83.6% | +998.2% | +118.6% | +36245.8% | +4523.8% | +121.5% | -12576.4% | -99.0% | -93.9% | -1300.9% | -111.4% | -37.0% | +897.2% | -92.5% | -69.4% | +307.1% | -92.6% | |
| ROIC | 342.7% | 126.3% | 89.2% | 82.9% | 157.8% | — | — | — | — | — | -23.1% | -0.3% | -0.1% | 0.7% | -1.1% | 0.3% | 2.1% | -0.1% | 0.7% | 0.1% | 0.4% |
| — | — | — | — | — | — | — | — | — | — | -1929.1% | -188.8% | -104.0% | +783.4% | -252.1% | +121.1% | +376.9% | -104.0% | -72.3% | -87.9% | -87.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | 0.05 | 0.05 | 0.05 | 0.05 | 0.58 | 0.50 | 0.52 | 0.53 | 0.54 | 0.52 |
| — | — | — | — | — | — | — | — | — | — | — | -92.1% | -91.0% | -91.1% | -91.3% | +6.8% | -4.1% | +1.0% | +0.7% | -2.6% | -5.9% | |
| Debt / EBITDA | 1.23 | 2.75 | 3.12 | 3.61 | 2.76 | 3.42 | 4.75 | 5.21 | 3.71 | 23.67 | — | 2.39 | 2.01 | 1.41 | 13.45 | 20.37 | 8.06 | 21.93 | 13.53 | 19.14 | 22.71 |
| — | -19.6% | -34.3% | -30.7% | -25.6% | -85.5% | — | +117.7% | +84.9% | +1577.4% | — | -88.2% | -75.1% | -93.6% | -0.6% | +6.4% | -64.5% | +106.1% | +33.6% | -9.2% | +165.9% | |
| Current Ratio | 0.71 | 0.61 | 0.84 | 0.86 | 0.71 | 0.96 | 0.90 | 0.88 | 0.89 | 0.83 | 0.85 | 1.73 | 1.70 | 1.56 | 1.68 | 1.21 | 1.07 | 0.91 | 0.85 | 2.00 | 1.91 |
| — | -35.6% | -7.3% | -2.5% | -20.2% | +15.0% | +5.5% | -49.2% | -47.4% | -46.9% | -49.1% | +43.3% | +59.2% | +70.9% | +97.3% | -39.6% | -44.1% | -67.9% | -62.3% | -17.9% | -25.8% | |
| Quick Ratio | 0.55 | 0.50 | 0.66 | 0.66 | 0.55 | 0.79 | 0.76 | 0.72 | 0.70 | 0.65 | 0.68 | 1.49 | 1.43 | 1.27 | 1.32 | 1.08 | 0.93 | 0.80 | 0.73 | 1.69 | 1.63 |
| — | -36.9% | -12.8% | -7.7% | -22.4% | +22.8% | +10.9% | -52.0% | -50.9% | -49.3% | -48.1% | +37.8% | +53.4% | +59.1% | +79.5% | -35.8% | -42.9% | -69.1% | -64.2% | -24.2% | -31.2% | |
| Interest Coverage | 6.31 | 92.00 | 81.00 | 17.43 | 14.50 | 4.08 | 5.13 | 5.92 | 7.77 | 0.90 | -12.44 | — | — | — | -17.82 | 6.99 | 23.05 | 0.74 | 7.26 | 8.58 | 1.35 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SUPN stock.
Supernus Pharmaceuticals, Inc.'s current P/E is 7.9x. The average P/E over the last 4 quarters is 13.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Supernus Pharmaceuticals, Inc.'s current operating margin is 21.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Supernus Pharmaceuticals, Inc.'s business trajectory between earnings reports.